Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers

Author(s): Pengfei Wang, Zheng Zeng, Caiji Lin, Jiali Wang, Wenwen Xu, Wenqing Ma, Qian Xiang, Huidi Liu, Shu-Lin Liu*.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 18 , 2020

Become EABM
Become Reviewer


Thrombospondin-1, an extracellular matrix protein, is the first identified natural angiogenesis inhibitor. Thrombospondin-1 participates in a great number of physiological and pathological processes, including cell-cell and cell-matrix interactions via a number of cell receptors, including CD36 and CD47, which plays a vital role in mediating inflammation and performs a promoting effect in pulmonary arterial vasculopathy and diabetes. Thrombospondin-1 consists of six domains, which combine with different molecules and participate in various functions in cancers, serving as a critical member in diverse pathways in cancers. Thrombospondin-1 works as a cancer promotor in some pathways but as a cancer suppressor in others, which makes it highly possible that its erroneous functioning might lead to opposite effects. Therefore, subdividing the roles of thrombospondin-1 and distinguishing them in cancers are necessary. Complex structure and multiple roles take disadvantage of the research and application of thrombospondin-1. Compared with the whole thrombospondin-1 protein, each thrombospondin- 1 active peptide performs an uncomplicated structure and, nevertheless, a specific role. In other words, various thrombospondin-1 active peptides may function differently. For instance, thrombospondin-1 could both promote and inhibit glioblastoma, which is significantly inhibited by the three type I repeats, a thrombospondin-1 active peptide but promoted by the fragment 167-569, a thrombospondin-1 active peptide consisting of the procollagen homology domain and the three type I repeats. Further studies of the functions of thrombospondin-1 active peptides and applying them reasonably are necessary. In addition to mediating cancerogenesis, thrombospondin-1 is also affected by cancer development, as reflected by its expression in plasma and the cancer tissue. Therefore, thrombospondin-1 may be a potential biomarker for pre-clinical and clinical application. This review summarizes findings on the multiple roles of thrombospondin-1 in cancer processes, with a focus on its use as a potential therapeutic target.

Keywords: Thrombospondin-1, cancer, cancer promotor, cancer suppressor, therapeutic target, active peptide, biomarker.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [2116 - 2136]
Pages: 21
DOI: 10.2174/1381612826666200128091506
Price: $65

Article Metrics

PDF: 31